Opendata, web and dolomites

PermeAbility SIGNED

PermeAbility - A non-invasive, side-effect-free diagnostic kit for intestinal disorders

Total Cost €


EC-Contrib. €






 PermeAbility project word cloud

Explore the words cloud of the PermeAbility project. It provides you a very rough idea of what is the project "PermeAbility" about.

proprietary    risk    solely    qualitative    burden    patients    reinforced    blood    evaluation    removal    unnecessary    surgeries    articles    poses    treatment    restricted    obesity    intestinal    structure    food    lesions    diagnosis    causing    organization    maintaining    bacteria    lifetag    billion    inflammation    disposing    cells    wall    bowel    threats    pain    diabetes    leaky    causes    economic    heavy    intestine    waste    symptoms    indirect    lgs    toxic    invasive    health    diagnostic    select    worldwide    leak    plasma    35    clinical    rupture    markers    direct    bleedings    arthritis    tightly    damage    stream    quality    decision    performed    revealing    stool    diagnosed    digestion    people    particles    acute    description    rheumatoid    diarrhea    dramatic    small    abdominal    ibd    reported    life    disease    permeability    inflammatory    connected    mri    compromise    besides    microcapsule    biopsy    assessing    though    clear    extensive    facts    gut    compromises    barrier    informed    form    normally    urges    colonoscopy    limited    ulcers    syndrome   

Project "PermeAbility" data sheet

The following table provides information about the project.


Organization address
postcode: 3060 197
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2019-01-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LIEFTAG LDA PT (CANTANHEDE) coordinator 50˙000.00


 Project objective

'Inflammatory Bowel Disease (IBD) is a form of acute inflammation to the small intestine that causes ulcers and extensive damage of the gut barrier causing it to rupture. This causes bleedings, abdominal pain, diarrhea, and a dramatic reduction of the quality of life. The intestinal barrier is normally a very well organised structure in which the cells are tightly connected maintaining the barrier. Moreover, IBD lesions compromise this intestinal organization and increases intestinal permeability, which is called leaky gut syndrome (LGS) being also a pre-disposing factor for several other health problems. LGS compromises digestion of food particles and removal of toxic waste products, and allows bacteria to 'leak' through the intestine to the blood stream. Besides in IBD, LGS is also common in people with health conditions such as obesity, rheumatoid arthritis and type 2 diabetes. Even though IBD poses significant threats to a patients’ health and a heavy direct and indirect economic burden, diagnosis of this condition is still limited assessing indirect parameters like general inflammation markers in plasma and stool and evaluation based by comparison on the patients symptoms description. The direct measures are also performed but are restricted to very invasive methods like biopsy or solely qualitative like MRI and microcapsule colonoscopy. In this way it is reported in several clinical articles a clear need for new diagnostic methods in IBD reinforced by facts like 35% of the performed surgeries for treatment revealing unnecessary and 1.9 billion people worldwide at risk for early lesions and IBD development not being diagnosed. In this way clinical practice urges for new methods for the assessment of lesions in the intestinal wall. Lifetag’s has developed PermeAbility, a new proprietary test to measure intestinal permeability to better select patients at high risk of IBD , leading to better informed clinical decision making, diagnosis, and treatment.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERMEABILITY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PERMEABILITY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ARON (2020)

Assay-Ready Organ Network

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

Nocturne (2019)

The eye as a window to the brain, extending lifelong brain health

Read More